SIGHT SCIENCES, INC. SGHT 深 滬
等待開盤 09-04 09:30:00 美东时间
3.80
-0.070
-1.81%
華盛通- 最 高3.87
- 今 開3.83
- 成交量 9.55万股
- 最 低 3.70
- 昨 收 3.87
- 總市值 1.99亿
- 52周最高 7.03
- 市盈率 靜 --
- 換手率 0.18%
- 52周最低 2.03
- 委 比 -41.67%
- 總股本 5236.74万
- 歷史最高 42.57
- 量 比 0.92
- 振 幅 4.39%
- 歷史最低 1.04
- 每 手 1
- 風險率 1.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO
Sight Sciences’ TearCare System has been included in the TFOS DEWS III report, a key evidence-based standard for dry eye disease (DED) management. The report highlights multiple studies demonstrating TearCare’s clinical efficacy, including its superiority in improving Tear Breakup Time and gland function compared to Restasis® in the SAHARA trial, and significant symptom alleviation in a single treatment shown in the OLYMPIA RCT. TearCare’s recogn...
09-02 20:05
Needham Reiterates Hold on Sight Sciencesto Hold
Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) from Hold to Hold.
08-29 00:44
Sight Sciences Announces Workforce Reduction Plan
The latest announcement is out from Sight Sciences ( ($SGHT) ). On August 27, 2...
08-28 04:35
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences, an eyecare technology company, announced that it will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025. The presentation will be accessible via webcast on the company's website. Sight Sciences focuses on developing innovative solutions for eye diseases, particularly glaucoma and dry eye, through minimally invasive technologies. Its products, including the OMNI Surgical System and TearCare® System, a...
08-26 20:05
美股大行评级 | Analog Devices获大摩、小摩、富国银行等四家机构"超配"评级，目标价最高升至310美元
今日重点评级关注：摩根大通：维持Analog Devices"超配"评级，目标价从300美元升至310美元；花旗：维持梅特勒-托利多"买入"评级，目标价从1400美元升至1600美元
08-22 09:57
What 4 Analyst Ratings Have To Say About Sight Sciences
Sight Sciences (NASDAQ:SGHT) has been analyzed by 4 analysts in the last three ...
08-22 03:00
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $4.5
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $3.6 to $4.5.
08-22 02:14
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Lake Street Upgrades Sight Sciences to Buy, Raises Price Target to $5
Lake Street analyst Frank Takkinen upgrades Sight Sciences (NASDAQ:SGHT) from Hold to Buy and raises the price target from $3 to $5.
08-09 06:18
Sight Sciences Raises Full-Year Revenue Guidance
An update from Sight Sciences ( ($SGHT) ) is now available. On August 7, 2025, ...
08-08 04:42
